{"id":45903,"date":"2025-09-25T14:23:21","date_gmt":"2025-09-25T08:53:21","guid":{"rendered":"https:\/\/financialtelegraph.in\/index.php\/2025\/09\/25\/perzea-launch-by-hetero-healthcare-and-enzene-supports-indias-vision-of-accessible-cancer-care\/"},"modified":"2025-09-25T14:23:21","modified_gmt":"2025-09-25T08:53:21","slug":"perzea-launch-by-hetero-healthcare-and-enzene-supports-indias-vision-of-accessible-cancer-care","status":"publish","type":"post","link":"https:\/\/financialtelegraph.in\/index.php\/2025\/09\/25\/perzea-launch-by-hetero-healthcare-and-enzene-supports-indias-vision-of-accessible-cancer-care\/","title":{"rendered":"Perzea Launch by Hetero Healthcare and Enzene Supports India\u2019s Vision of Accessible Cancer Care"},"content":{"rendered":"<div>\n<p><img loading=\"lazy\" width=\"1200\" height=\"675\" src=\"https:\/\/financialtelegraph.in\/wp-content\/uploads\/2025\/09\/2526009559-Perzea-Launch-by-Hetero-.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Hetero Healthcare and Enzene launch affordable biosimilar Perzea-pnn\" decoding=\"async\"><\/p>\n<p><span data-sheets-root=\"1\"><strong>Hyderabad (Telangana) [India], September 25: <\/strong><\/span>Reinforcing the Government of India\u2019s mission to provide equitable healthcare, Hetero Healthcare Limited, in partnership with Enzene Biosciences, has launched\u00a0<strong>Perzea<\/strong>, its most affordable\u00a0<strong>biosimilar Pertuzumab<\/strong>\u00a0for HER2-positive breast cancer. This initiative underlines the critical need for\u00a0<strong>advanced cancer treatment accessibility<\/strong>\u00a0in the country.<\/p>\n<p><strong>Closing the Treatment Gap<\/strong><br \/>\nPertuzumab, a globally accepted monoclonal antibody therapy, significantly improves outcomes when used with trastuzumab and chemotherapy. However, for many Indian patients, high costs have been a deterrent. Perzea bridges this divide, offering patients a more affordable yet effective option.<\/p>\n<p>\u201cHetero Healthcare is proud to support the nation\u2019s healthcare goals,\u201d said Mr. M. Srinivas Reddy, Managing Director. \u201c<strong>Perzea represents our responsibility to provide Indian patients with world-class therapies at a fraction of global costs.<\/strong>\u201d<\/p>\n<p><strong>Strengthening Oncology Access in India<\/strong><br \/>\nThis launch also reflects India\u2019s growing role as a hub for biosimilar development. By collaborating with Enzene Biosciences, Hetero Healthcare demonstrates how partnerships can combine science, scale, and affordability to improve patient outcomes.<\/p>\n<p><strong>About Hetero Healthcare<\/strong><br \/>\nHetero Healthcare Limited has been a leader in oncology, antiretrovirals, and critical care therapies. Its mission to deliver affordable healthcare solutions across India continues to make a profound impact on millions of lives. More:\u00a0<a href=\"http:\/\/www.heterohealthcare.com\/\" target=\"_new\" rel=\"noopener\">www.heterohealthcare.com<\/a><\/p>\n<p><strong>About Enzene Biosciences<\/strong><br \/>\nEnzene is advancing biologics manufacturing through its EnzeneX<img decoding=\"async\" src=\"https:\/\/financialtelegraph.in\/wp-content\/uploads\/2025\/09\/2122-5.png\" alt=\"\u2122\" class=\"wp-smiley\" style=\"height: 1em; max-height: 1em;\"> technology, aiming to reduce monoclonal antibody production costs significantly. Its focus on innovation and efficiency supports global access to critical therapies. More:\u00a0<a href=\"http:\/\/www.enzene.com\/\" target=\"_new\" rel=\"noopener\">www.enzene.com<\/a><\/p>\n<p><span data-sheets-root=\"1\"><strong>Disclaimer:<\/strong> This article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hyderabad (Telangana) [India], September 25: Reinforcing the Government of India\u2019s mission to provide equitable healthcare, Hetero Healthcare Limited, in partnership with Enzene Biosciences, has launched\u00a0Perzea, its most affordable\u00a0biosimilar Pertuzumab\u00a0for HER2-positive &hellip; <a href=\"https:\/\/financialtelegraph.in\/index.php\/2025\/09\/25\/perzea-launch-by-hetero-healthcare-and-enzene-supports-indias-vision-of-accessible-cancer-care\/\" class=\"more-link\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":45904,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[99],"tags":[680],"class_list":["post-45903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-health","entry"],"_links":{"self":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/45903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/comments?post=45903"}],"version-history":[{"count":0,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/45903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media\/45904"}],"wp:attachment":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media?parent=45903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/categories?post=45903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/tags?post=45903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}